Transportability Analysis—A Tool for Extending Trial Results to a Representative Target Population
JAMA Network Open · 30.01.2024 · 7 (1) · e2346302
DOI: 10.1001/jamanetworkopen.2023.46302 ↗Kurz gefasst
Kommentar in der Zeitschrift JAMA Network Open, online erschienen am 30.01.2024. Verfasst von Kosuke Inoue und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Social Epidemiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIBIB NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Randomized controlled trials estimate the causal effect between an intervention and the outcome on a target population through careful design to control for potential biases.However, this effect varies based on how the target population is defined, and in practice, physicians are tasked with determining the relevance of RCT results for patient populations with different characteristics than the study population.1,2 Approaches that extend inferences from a study population to a representative target, such as transportability analysis, provide powerful tools to address questions like who would most benefit from a clinical intervention.3,4 Lung cancer remains the leading cause of cancer-related death worldwide, driven by the advanced disease at the time of diagnosis.While screening the general population using chest radiographs showed no benefit, evidence from two large trials showed lung cancer mortality benefit when screening high-risk populations based on age and smoking history using low-dose computed tomography (LDCT).The National Lung Screening Trial enrolled 53,454 participants randomly assigned to undergo three annual screens with either low-dose CT (n=26,722) or chest radiography (n=26,732).5 The trial reported a 20% (95% CI, 6.8-26.7%)relative risk reduction of lung cancer-related mortality in men and women compared to chest radiography at 6.5-year follow-up.The Dutch/Belgian randomized lung cancer screening trial (NELSON) reported its survival results involving 15,792 participants who were screened at 1, 3, and 6 years, showing 24% (95% CI, 7-39%) relative risk reduction of lung cancer-related mortality in men undergoing LDCT screening as compared to no screening at 10-year follow-up.6 These trials show compelling evidence for the studied
Autor:innen und Institutionen
- Department of Social Epidemiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Hakubi Center, Kyoto University, Kyoto, Japan.
- Medical & Imaging Informatics Group, Department of Radiological Sciences, David Geffen School of Medicine, UCLA, Los Angeles, California.
- Department of Bioengineering, UCLA Samueli School of Engineering, Los Angeles, California.
Förderung
- NIBIB NIH HHS
- NCI NIH HHS
Zitieren
APA
Inoue, K., & Hsu, W. (2024). Transportability Analysis—A Tool for Extending Trial Results to a Representative Target Population. JAMA Network Open, 7(1), e2346302. https://doi.org/10.1001/jamanetworkopen.2023.46302
Vancouver
Inoue K, Hsu W. Transportability Analysis—A Tool for Extending Trial Results to a Representative Target Population. JAMA Network Open. 2024;7(1):e2346302. doi:10.1001/jamanetworkopen.2023.46302
BibTeX
@article{Inoue2024,
author = {Inoue, Kosuke and Hsu, William},
title = {Transportability Analysis—A Tool for Extending Trial Results to a Representative Target Population},
journal = {JAMA Network Open},
year = {2024},
volume = {7},
number = {1},
pages = {e2346302},
doi = {10.1001/jamanetworkopen.2023.46302}
}
EUVIMED